canrenone

Canrenone is a potassium-sparing diuretic and an active metabolite of spironolactone. It is formed in the liver during the metabolism of spironolactone and contributes to the pharmacological effects of the parent drug. Like spironolactone, canrenone acts as an antagonist of the mineralocorticoid receptor.

Pharmacology is characterized by inhibition of aldosterone’s effects in the distal nephron, leading to increased sodium excretion and reduced potassium loss. This results in diuresis and often blood pressure reduction. Canrenone’s activity is part of the overall mineralocorticoid receptor antagonism produced by spironolactone therapy.

Pharmacokinetics are described in the context of spironolactone treatment; canrenone is generated in the body from spironolactone and is pharmacologically active. Excretion occurs primarily via the urine.

Clinical use is typically as part of spironolactone therapy rather than as a standalone drug in most regions. Canrenone is discussed in pharmacology as one of the active metabolites that contribute to the diuretic and antihypertensive effects of spironolactone. It has been studied in various contexts to understand the duration and magnitude of aldosterone antagonism.

Adverse effects align with those of potassium-sparing diuretics and spironolactone, including the potential for hyperkalemia, particularly in patients with renal impairment or those taking other potassium-sparing agents. Other possible effects include dehydration, electrolyte disturbances, and gastrointestinal symptoms.

See also: Spironolactone; Mineralocorticoid receptor antagonists; Aldosterone antagonists.